[Why patent-protected drugs' cost efficiency should be compared with generic preparations].
Sjukvårdsavdelningen, Socialstyrelsen.
Fredrik
F
Berggren
Douglas
D
Lundin
Joakim
J
Ramsberg
D003362:Cost-Benefit Analysis; D016527:Drug Costs; D016568:Drugs, Generic / Q000191:economics*; D006801:Humans; D010330:Patents as Topic / Q000331:legislation & jurisprudence*
D016568:Drugs, Generic